Format

Send to

Choose Destination
Trends Biotechnol. 2014 Jan;32(1):54-60. doi: 10.1016/j.tibtech.2013.10.002. Epub 2013 Oct 31.

Microbials for the production of monoclonal antibodies and antibody fragments.

Author information

1
Vienna University of Technology, Institute of Chemical Engineering, Research Area Biochemical Engineering, Gumpendorfer Strasse 1a, A-1060 Vienna, Austria.
2
Graz University of Technology, Institute of Molecular Biotechnology, Graz, Austria.
3
Austrian Centre of Industrial Biotechnology (ACIB GmbH), Graz, Austria.
4
Vienna University of Technology, Institute of Chemical Engineering, Research Area Biochemical Engineering, Gumpendorfer Strasse 1a, A-1060 Vienna, Austria. Electronic address: christoph.herwig@tuwien.ac.at.

Abstract

Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.

KEYWORDS:

antibody fragment; mammalian cell; microbial organism; monoclonal antibody; recombinant protein production

PMID:
24183828
PMCID:
PMC3906537
DOI:
10.1016/j.tibtech.2013.10.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center